Sugi Predict

Sugi Predict / Compounds / SCHEMBL255049

SCHEMBL255049

SCHEMBL255049

NCCCCCCO[PH](=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DNM1 Q05193 4/20 0.38
▸ CA12 O43570 2/20 0.38
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA3 P07451 2/20 0.38
▸ CA4 P22748 2/20 0.38
▸ CA6 P23280 2/20 0.38
▸ CA5A P35218 2/20 0.38
▸ CA7 P43166 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ CA14 Q9ULX7 2/20 0.38
▸ CA5B Q9Y2D0 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ BLM P54132 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ PLG P00747 1/20 0.36
▸ THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28579281 1.00 DNM1 (0.38) DNM1CA12CA1CA2CA3
SCHEMBL13048579 0.98 — —
Phosphonic Acid SCHEMBL9472597 0.95 NFKB1 (0.33) DNM1CA12CA1CA2CA3
Ethylenediamine SCHEMBL23064434 0.90 — —
SCHEMBL2184363 0.90 — —
Ethylenediamine SCHEMBL9511265 0.90 — —
Ethylenediamine SCHEMBL8636113 0.88 — —
SCHEMBL2467729 0.87 LPAR3 (0.32) —
SCHEMBL17061016 0.87 LPAR3 (0.32) —
SCHEMBL11744958 0.87 LPAR3 (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257745-A1 Circular siRNAs BANK OF AMERICA, N.A. 2023-08-17 — — US disclosed
US-20230167441-A1 Segmented Nucleic Acids ZHONG MINGHONG (US) 2023-06-01 — — US disclosed
US-9290531-B2 Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections Universitätsklinikum Freiburg (DE) 2016-03-22 — — US disclosed
WO-2014118267-A1 LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES SANTARIS PHARMA A/S (DK) 2014-08-07 — — WO disclosed
US-20140050741-A1 SYNTHETIC LTA MIMETICS AND USE THEREOF AS VACCINE COMPONENT FOR THERAPY AND/OR PROPHYLAXIS AGAINST GRAM-POSITIVE INFECTIONS UNIVERSITEIT LEIDEN (NL) 2014-02-20 — — US disclosed
US-8563528-B2 Antisense oligomers targeting PCSK9 SANTARIS PHARMA A/S (DK) 2013-10-22 — — US disclosed
US-20130123334-A1 NOVEL SIRNA STRUCTURES QUARK PHARMACEUTICALS, INC. 2013-05-16 — — US disclosed
US-8361980-B2 Pharmaceutical compositions for treatment of microRNA related diseases SANTARIS PHARMA A/S (DK) 2013-01-29 — — US disclosed
US-20120295955-A1 RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 SANTARIS PHARMA A/S (DK) 2012-11-22 — — US disclosed
US-20120288933-A1 SYNTHETIC MIMICS OF MIR-34 MIRNA THERAPEUTICS, INC. 2012-11-15 — — US disclosed
US-20090181916-A1 LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR SANTARIS PHARMA A/S (DK) 2009-07-16 — — US disclosed
WO-2009071082-A2 RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION SANTARIS PHARMA A/S (DK) 2009-06-11 — — WO disclosed
US-20090143326-A1 MICROMIRs SANTARIS PHARMA A/S (DK) 2009-06-04 — — US disclosed
WO-2009068033-A2 LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR SANTARIS PHARMA A/S (DK) 2009-06-04 — — WO disclosed
CN-100467448-C Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use AVENTIS PHARMA GMBH (DE) 2009-03-11 — — CN disclosed
US-20090005335-A1 COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION SANTARIS PHARMA A/S (DK) 2009-01-01 — — US disclosed
US-20080318894-A1 RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 SANTARIS PHARMA A/S (DK) 2008-12-25 — — US disclosed
WO-2008138904-A2 RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 SANTARIS PHARMA A/S (DK) 2008-11-20 — — WO disclosed
US-7329515-B2 Solid support for the synthesis of 3′-amino oligonucleotides SIGMA-ALDRICH CO. (US) 2008-02-12 — — US disclosed
CN-1662495-A Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use AVENTIS PHARMA GMBH (DE) 2005-08-31 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295955-A1 RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 ERBB3, EGFR, ERBB2 DNM1 1406/4885CA12 4353/4885CA1 4631/4885
US-20090005335-A1 COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION CTNNB1, CTNNA1, WNT1 DNM1 2275/4885CA12 4482/4885CA1 4799/4885
US-20090143326-A1 MICROMIRs TRDMT1, METTL16, MTNR1A DNM1 636/4885CA12 2290/4885CA1 2707/4885
US-20090181916-A1 LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR AR, ESRRB, ESRRA DNM1 1389/4885CA12 4723/4885CA1 4803/4885
US-20120288933-A1 SYNTHETIC MIMICS OF MIR-34 RBM39, RPL34, AGO2 DNM1 2345/4885CA12 4507/4885CA1 3258/4885
US-20080318894-A1 RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 ERBB3, EGFR, ERBB2 DNM1 1406/4885CA12 4353/4885CA1 4631/4885
US-20140050741-A1 SYNTHETIC LTA MIMETICS AND USE THEREOF AS VACCINE COMPONENT FOR THERAPY AND/OR PROPHYLAXIS AGAINST GRAM-POSITIVE INFECTIONS LTA, LTN1, LTC4S DNM1 2372/4885CA12 3008/4885CA1 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.